Results 1 to 10 of about 57,349 (269)

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development [PDF]

Pathogens, 2023
The present use of mRNA vaccines against COVID-19 has shown for the first time the potential of mRNA vaccines for infectious diseases. Here we will summarize the current knowledge about improved mRNA vaccines, i.e., the self-amplifying mRNA (saRNA ...
Christin Schmidt, Barbara S. Schnierle
doaj   +6 more sources

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines [PDF]

Molecular Therapy: Nucleic Acids, 2023
To be effective, RNA vaccines require both in situ translation and the induction of an immune response to recruit cells to the site of immunization. These factors can pull in opposite directions with the inflammation reducing expression of the vaccine ...
John S. Tregoning, David C. Stirling, Ziyin Wang, Katie E. Flight, Jonathan C. Brown, Anna K. Blakney, Paul F. McKay, Robert F. Cunliffe, Valarmathy Murugaiah, Christopher B. Fox, Mitchell Beattie, Ying K. Tam, Cecilia Johansson, Robin J. Shattock   +13 more
doaj   +6 more sources

A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses [PDF]

Frontiers in Immunology
IntroductionYellow fever (YFV) and Zika (ZIKV) viruses cause significant morbidity and mortality, despite the existence of an approved YFV vaccine and the development of multiple ZIKV vaccine candidates to date.
Peter Battisti, Matthew R. Ykema, Darshan N. Kasal, Madeleine F. Jennewein, Samuel Beaver, Abbie E. Weight, Derek Hanson, Jasneet Singh, Julie Bakken, Noah Cross, Pauline Fusco, Jacob Archer, Sierra Reed, Alana Gerhardt, Justin G. Julander, Corey Casper, Corey Casper, Corey Casper, Corey Casper, Emily A. Voigt   +19 more
doaj   +4 more sources

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19 [PDF]

Vaccines
SARS-CoV-2 virus, the causative agent of COVID-19, has produced the largest pandemic in the 21st century, becoming a very serious health problem worldwide.
Noelia Silva-Pilipich, Uxue Beloki, Laura Salaberry, Cristian Smerdou   +3 more
doaj   +4 more sources

Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development [PDF]

Viruses
Self-amplifying RNA is synthetic nucleic acid engineered to replicate within cells without generating viral particles. Derived from alphavirus genomes, saRNA retains the non-structural elements essential for replication while replacing the structural ...
Thomas Vallet, Marco Vignuzzi
doaj   +4 more sources

Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin [PDF]

Molecular Therapy: Nucleic Acids, 2019
In this work, we studied the expression kinetics and innate immune response of a self-amplifying mRNA (sa-RNA) after electroporation and lipid-nanoparticle (LNP)-mediated delivery in the skin of mice. Intradermal electroporation of the sa-RNA resulted in
Hanne Huysmans, Zifu Zhong, Joyca De Temmerman, Barbara L. Mui, Ying K. Tam, Séan Mc Cafferty, Arlieke Gitsels, Daisy Vanrompay, Niek N. Sanders   +8 more
doaj   +3 more sources

A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague [PDF]

Frontiers in Microbiology, 2023
Mice were immunized with a combination of self-amplifying (sa) RNA constructs for the F1 and V antigens of Yersinia pestis at a dose level of 1 μg or 5 μg or with the respective protein sub-units as a reference vaccine.
Robin John Shattock, Voahangy Andrianaivoarimanana, Paul F. McKay, Lovasoa Nomena Randriantseheno, Valarmathy Murugaiah, K. Samnuan, Paul Rogers, John S. Tregoning, Minoarisoa Rajerison, Kristoffer M. Moore, Thomas Robert Laws, E. Diane Williamson   +11 more
doaj   +2 more sources

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability [PDF]

npj Vaccines, 2022
mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage ...
Emily A. Voigt, Alana Gerhardt, Derek Hanson, Madeleine F. Jennewein, Peter Battisti, Sierra Reed, Jasneet Singh, Raodoh Mohamath, Julie Bakken, Samuel Beaver, Christopher Press, Patrick Soon-Shiong, Christopher J. Paddon, Christopher B. Fox, Corey Casper   +14 more
doaj   +3 more sources

A sort and sequence approach to dissect heterogeneity of response to a self-amplifying RNA vector in a novel human muscle cell line [PDF]

Molecular Therapy: Nucleic Acids
Self-amplifying RNA (saRNA) is an extremely promising platform because it can produce more protein for less RNA. We used a sort and sequence approach to identify host cell factors associated with transgene expression from saRNA; the hypothesis was that ...
Rachel D. Barton, John S. Tregoning, Ziyin Wang, Daniel Gonçalves-Carneiro, Radhika Patel, Paul F. McKay, Robin J. Shattock   +6 more
doaj   +2 more sources

Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport [PDF]

npj Vaccines
Self-amplifying RNA (saRNA)-based vaccines have emerged as a potent and durable RNA vaccine platform relative to first generation mRNA vaccines. However, RNA vaccine platforms trigger undesirable side effects at protective doses, underscoring the need ...
Jason A. Wojcechowskyj, Robyn M. Jong, Imre Mäger, Britta Flach, Paul V. Munson, Progya P. Mukherjee, Barbara Mertins, Katherine R. Barcay, Thomas Folliard   +8 more
doaj   +2 more sources